US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

BlossomHill Therapeutics (BLSM): Demand Blossoms as Books Near the Finish Line

BlossomHill Therapeutics (BLSM): IPO Falls Flat After Aggressive Upsizing

IPOs and Secondary Offerings

Equity Capital Markets

Blossomhill Therapeutics / Equity Capital Markets

<ul>
<li>BlossomHill is advancing a precision oncology pipeline led by BH-30643, an OMNI-EGFR inhibitor targeting resistant EGFR-mutant NSCLC populations.</li>
<li>IPO proceeds will primarily fund BH-30643’s Phase 1/2 SOLARA trial and potential registrational Phase 2 development pathway.</li>
<li>Backed by notable biotech investors, BlossomHill enters public markets as an early-stage oncology company with significant clinical execution risk and upside potential.</li>
</ul>


BlossomHill is advancing a precision oncology pipeline led by BH-30643, an OMNI-EGFR inhibitor targeting resistant EGFR-mutant NSCLC populations.
IPO proceeds will primarily fund BH-30643’s Phase 1/2 SOLARA trial and potential registrational Phase 2 development pathway.
Backed by notable biotech investors, BlossomHill enters public markets as an early-stage oncology company with significant clinical execution risk and upside potential.


BlossomHill Therapeutics (BLSM): Phase 1/2 Lung Cancer Biotech Sets Terms for IPO, Debuting Friday